Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Survivors share their stories to shape better cancer Follow-Up care

NCT ID NCT03515993

Knowledge-focused Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 people who are currently cancer-free will answer questionnaires about their quality of life, anxiety, sexual health, and more. The goal is to learn what matters most to survivors so doctors can improve follow-up care. No new treatments or drugs are being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2019

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Gynecologic cancer patients after primary treatment attending participating hospitals for routine follow-up.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological proven gynecological cancer (cervical, endometrial, ovarian (including fallopian tube and peritoneal primary), vulva). * FIGO stage I-IV before completion of primary therapy. * Disease-free without any evidence of relapse: no symptoms or signs potentially indicating recurrent disease (assessed according to standard clinical parameters using physical and gynecological examination, blood tests, CA 125 (ovarian cancer), or radiological imaging techniques). * At least 6 months but no more than 5 years since completion of primary treatment. * Performance status 0, 1 or 2 (WHO scale). * Age ≥ 18 years. * Ability to understand and fill out questionnaires. * Written informed consent according to ICH/GCP, and national/local regulations. Exclusion Criteria: * Other cancer diagnosis in the past 5 years. * Patients participating in interventional clinical studies with Quality of Life as primary endpoint. * Any psychological (including pre-existing psychiatric disorders), familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial cancer fallopian tube cancer female reproductive organ cancer ovarian cancer primary peritoneal carcinoma vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gynecologic cancer

Contacts and locations

Locations

  • Azienda Ospedaliera Ordine Mauriziano di Torino

    Torino, Italy

  • Centre Hospitalier Chretien (CHC) - CHC MontLegia

    Liège, Belgium

  • Complejo Hospitalario de Navarra

    Pamplona, Spain

  • East Kent Hospitals University NHS Foundation Trust - Queen Elizabeth The Queen Mother Hospita

    Margate, Kent, CT9 4AN, United Kingdom

  • HELIOS Kliniken - Helios Klinikum Wuppertal - Klin. Univ. Witten / Herdecke

    Wuppertal, Germany

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario San Carlos

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • King Hussein Cancer Center

    Amman, 11941, Jordan

  • Medical University Of Gdansk

    Gdansk, PL 80 211, Poland

  • Medical University of Graz

    Graz, 8036, Austria

  • NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital

    Glasgow, United Kingdom

  • Northampton General Hospital NHS Trust

    Cliftonville, Northampton, NN1 5BD, United Kingdom

  • Ospedale San Gerardo

    Monza, Italy

  • Radboudumc - Radboud University Medical Center Nijmegen

    Nijmegen, NL 6525, Netherlands

  • UMC-Academisch Ziekenhuis Utrecht

    Utrecht, NL 3584 CX, Netherlands

  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel

    Kiel, Germany

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • ZNA Jan Palfijn

    Merksem, Belgium

  • ZNA Middelheim

    Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.